Trebananib
Kidney Disease
Amgenprotein_peptidePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
5 Active assets in the Kidney Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Hydroxyurea Theravia | Phase 4 | BB |
nc-503 Bellus Health Inc. - a GSK company | Phase 2/3 | B |
VOLITINIB AstraZeneca | Phase 3 | B |
SEVELAMER Genzyme, a Sanofi Company | Phase 3 | B |
LANTHANUM CARBONATE HYDRATE University of Illinois at Chicago | Phase 2 | B |
View all 19 →
Same molecule, other indications
Trebananib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →